Wee Joo Chng

35.8k total citations · 3 hit papers
386 papers, 11.3k citations indexed

About

Wee Joo Chng is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Wee Joo Chng has authored 386 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 231 papers in Molecular Biology, 208 papers in Hematology and 112 papers in Oncology. Recurrent topics in Wee Joo Chng's work include Multiple Myeloma Research and Treatments (160 papers), Protein Degradation and Inhibitors (93 papers) and Lymphoma Diagnosis and Treatment (40 papers). Wee Joo Chng is often cited by papers focused on Multiple Myeloma Research and Treatments (160 papers), Protein Degradation and Inhibitors (93 papers) and Lymphoma Diagnosis and Treatment (40 papers). Wee Joo Chng collaborates with scholars based in Singapore, United States and China. Wee Joo Chng's co-authors include Jianbiao Zhou, Rafaël Fonseca, Siok‐Bian Ng, Chonglei Bi, Phaik Ju Teoh, Tae‐Hoon Chung, P. Leif Bergsagel, Sanjay De Mel, Angela Dispenzieri and Qiang Yu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Wee Joo Chng

359 papers receiving 11.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IMWG consensus on risk stratification in multiple myeloma

2013 413 citations Wee Joo Chng, Angela Dispenzieri et al. Leukemia profile →
Enabling Technologies for Personalized and Precision Medicine

2020 264 citations Wee Joo Chng et al. profile →
Identification of differential RNA modifications from nanopore direct RNA sequencing with xPore

2021 197 citations Jing Yuan Chooi, Wee Joo Chng et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wee Joo Chng Singapore	58	7.2k	4.0k	3.6k	1.6k	1.6k	386	11.3k
Klaus Podar United States	63	8.7k 1.2×	6.6k 1.6×	4.6k 1.3×	1.8k 1.1×	1.3k 0.8×	186	12.8k
Andrew H. Wei Australia	43	7.4k 1.0×	5.3k 1.3×	2.8k 0.8×	1.6k 1.0×	971 0.6×	258	11.7k
William S. Dalton United States	59	6.8k 0.9×	2.4k 0.6×	5.7k 1.6×	2.3k 1.4×	2.3k 1.5×	132	11.8k
Pierfrancesco Tassone Italy	65	7.5k 1.1×	2.9k 0.7×	3.9k 1.1×	1.6k 1.0×	3.8k 2.4×	317	11.8k
Hubert Serve Germany	59	8.5k 1.2×	6.8k 1.7×	3.1k 0.9×	1.7k 1.1×	2.9k 1.8×	299	15.5k
Anthony Letai United States	62	12.2k 1.7×	3.7k 0.9×	4.5k 1.3×	2.9k 1.8×	2.1k 1.3×	175	18.2k
Maria R. Baer United States	54	5.3k 0.7×	6.3k 1.6×	3.6k 1.0×	937 0.6×	1.0k 0.7×	393	11.6k
Elisabeth Paietta United States	61	4.7k 0.7×	7.8k 1.9×	3.0k 0.8×	1.4k 0.9×	773 0.5×	278	12.9k
Martin Sattler United States	55	4.3k 0.6×	3.1k 0.8×	2.4k 0.7×	1.2k 0.7×	764 0.5×	151	8.6k
Robert Z. Orlowski United States	66	13.2k 1.8×	9.7k 2.4×	8.3k 2.3×	1.5k 0.9×	1.4k 0.9×	514	18.6k

Countries citing papers authored by Wee Joo Chng

Since Specialization

Citations

This map shows the geographic impact of Wee Joo Chng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wee Joo Chng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wee Joo Chng more than expected).

Fields of papers citing papers by Wee Joo Chng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wee Joo Chng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wee Joo Chng. The network helps show where Wee Joo Chng may publish in the future.

Co-authorship network of co-authors of Wee Joo Chng

This figure shows the co-authorship network connecting the top 25 collaborators of Wee Joo Chng. A scholar is included among the top collaborators of Wee Joo Chng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wee Joo Chng. Wee Joo Chng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Jianbiao, et al.. (2025). Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails. Blood. 146(13). 1550–1560. 1 indexed citations

Brunmeir, Reinhard, Ying Li, Junli Yan, et al.. (2025). EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML. Leukemia. 39(3). 650–662. 1 indexed citations

Nagarajan, Chandramouli, Gin Gin Gan, Chor Sang Chim, et al.. (2025). Imaging in plasma cell disorders—consensus recommendations of the Asian myeloma network bone imaging workgroup. The Lancet Regional Health - Western Pacific. 59. 101597–101597.

Hue, Susan Swee‐Shan, et al.. (2025). Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications. The Lancet Regional Health - Western Pacific. 62. 101550–101550. 2 indexed citations

Ding, Ling‐Wen, Jia Li, Benedict Yan, et al.. (2024). A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy. Clinical Cancer Research. 30(10). 2170–2180. 1 indexed citations

Choo, Joan, Jieming Zeng, Sudipto Bari, et al.. (2024). Abstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial). Cancer Research. 84(7_Supplement). CT160–CT160. 1 indexed citations

Aoki, Naomi, Wenming Chen, Wee Joo Chng, et al.. (2024). The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR). BMC Medical Research Methodology. 24(1). 102–102.

Teoh, Phaik Ju, et al.. (2024). Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica. 110(5). 1074–1091. 1 indexed citations

Tang, Xiao, Esther Hian Li Chan, Sanjay De Mel, et al.. (2024). Evaluating the Comprehensive Geriatric Assessment Model As an Assessment Tool to Predict Chemotoxicity in Elderly Patients with Lymphoma. Blood. 144(Supplement 1). 388–388.

10.

Ye, Zhiyong, Alice M.S. Cheung, Yufen Goh, et al.. (2021). Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Molecular Cancer Therapeutics. 20(9). 1702–1712. 37 indexed citations

11.

Chong, Phyllis S.Y., et al.. (2021). SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic PTP4A3 through Chromatin Remodeling in t(4;14) Multiple Myeloma. Cancer Research. 81(9). 2332–2344. 16 indexed citations

12.

Dimopoulos, Meletios Α., S. Vincent Rajkumar, Sagar Lonial, et al.. (2021). Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM). Blood. 138(Supplement 1). 1656–1656. 2 indexed citations

13.

Zhou, Jianbiao, et al.. (2021). Single-Cell Multi-Omic Analysis Uncovers Comprised Immune Function and Primary Resistance Mechanism in Acute Myeloid Leukemia. Blood. 138(Supplement 1). 378–378.

14.

Tan, Marcus Chun Jin, Isaac KS Ng, Zhaojin Chen, et al.. (2017). Clinical implications of DNMT3A mutations in a Southeast Asian cohort of acute myeloid leukaemia patients. Journal of Clinical Pathology. 70(8). 669–676. 11 indexed citations

15.

Ng, Christopher, Chun Kiat Lee, Zhaojin Chen, et al.. (2017). CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay. Journal of Clinical Pathology. 71(6). 522–531. 12 indexed citations

16.

Zhou, Jianbiao, Chonglei Bi, Phyllis S.Y. Chong, et al.. (2016). LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell–like Transcriptional Program in AML. Molecular Cancer Research. 15(3). 294–303. 30 indexed citations

17.

Kong, Li Ren, Kian Ngiap Chua, Wen Jing Sim, et al.. (2015). MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. Molecular Cancer Therapeutics. 14(7). 1750–1760. 41 indexed citations

18.

Chong, Phyllis S.Y., Jianbiao Zhou, Shaw-Cheng Liu, et al.. (2014). LEO1 Is Regulated by PRL-3 and Mediates Its Oncogenic Properties in Acute Myelogenous Leukemia. Cancer Research. 74(11). 3043–3053. 28 indexed citations

19.

Kudo, Ko, Chihaya Imai, Takahiro Kamiya, et al.. (2013). T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing. Cancer Research. 74(1). 93–103. 159 indexed citations

20.

Chng, Wee Joo, Shaji Kumar, Scott VanWier, et al.. (2007). Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. Cancer Research. 67(7). 2982–2989. 195 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact